Infections are an important cause of morbidity and mortality in patients with lower-risk myelodysplastic syndromes (LR-MDS). Studies regarding risk factors for infections are, however, limited in this population. This study aimed to investigate the prevalence and risk factors for infections and infection-related death in patients with LR-MDS. The study included 2,552 patients from the European MDS (EUMDS) Registry, which prospectively collects observational data on newly diagnosed MDS patients from 17 countries. The prevalence of infections and infection-related death was determined. Risk factors for infections and infection-related death occurring within 1 year from diagnosis were analyzed in separate multivariable logistic regression models. A third model that only included LR-MDS patients who experienced an infectious episode within the first year after diagnosis was used to analyze risk factors associated with infection-related death in patients with an infectious episode. The prevalence of infections was 7.6%, and 24.6% of all deaths were due to infections. In multivariable analysis, an independent association with increased risk for infections was found for hemoglobin level <8 g/dL, platelet count <50x109/L, absolute neutrophil count <0.8x109/L, intermediate/poor/very poor cytogenetics, and having received red blood cell transfusions at baseline. An independent association with increased risk of infection-related death was found for older age at diagnosis, hemoglobin level <8 g/dL, and platelet count <50x109/L. Patients with an increased risk of infections could benefit from close monitoring, especially in the first months after diagnosis. Future research should focus on the causality and severity of infections and risk factors over time, to provide more guidance for monitoring.

Dep of Clinical Hematology Inst of Hematology and Blood Transfusion Praha Czech Republic

Dep of Haematology Aberdeen Royal Infirmary Aberdeen

Dep of Hematology Aviv Sourasky Medical Center and Medical Faculty Aviv University Aviv 6423906

Dep of Hematology Democritus University of Thrace Medical School University Hospital of Alexandroupolis Alexandroupolis

Dep of Hematology Radboud University Medical Center Nijmegen

Dep of Internal Medicine 5 Innsbruck Medical University Innsbruck

Dep of Internal Medicine IUCT Oncopole Toulouse University Hospital Toulouse

Dep of Medicine Div Hematology University of Patras Medical School and Olympion General clinic Patras

Dep of Medicine Karolinska Institutet and Department of Hematology Karolinska University Hospital Stockholm

Dep of Molecular Medicine University of Pavia Pavia Italy; Dep of Hematology Oncology Fondazione IRCCS Policlinico San Matteo Pavia

Dep of Tumor Immunology Nijmegen Center for Molecular Life Sciences Radboud University Medical Center Nijmegen

Epidemiology and Cancer Statistics Group Department of Health Sciences University of York York

Haematological Malignancy Diagnostic Service Leeds Cancer Centre St James's University Hospital and Leeds Teaching Hospitals NHS Trust Leeds

Instituto de Investigación Sanitaria La Fe Hospital Universitario y Politécnico La Fe and CIBERONC Valencia

Service d'Hématologie Hôpital Saint Louis Assistance Publique des Hôpitaux de Paris and Université Paris 7 Paris

Zobrazit více v PubMed

Malcovati L, Hellström-Lindberg E, Bowen D, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood. 2013;122(17):2943-2964. PubMed PMC

Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079-2088. PubMed

Greenberg PL, Tuechler H, Schanz J, et al. Revised International Prognostic Scoring System for myelodysplastic syndromes. Blood. 2012;120(12):2454-2465. PubMed PMC

Sekeres MA, Taylor J. Diagnosis and treatment of myelodysplastic syndromes: a review. JAMA. 2022;328(9):872-880. PubMed

Carraway HE, Saygin C. Therapy for lower-risk MDS. Hematology Am Soc Hematol Educ Program. 2020;2020(1):426-433. PubMed PMC

Dayyani F, Conley AP, Strom SS, et al. Cause of death in patients with lower-risk myelodysplastic syndrome. Cancer. 2010;116(9):2174-2179. PubMed PMC

Mądry K, Lis K, Fenaux P, et al. Cause of death and excess mortality in patients with lower-risk myelodysplastic syndromes (MDS): a report from the European MDS Registry. Br J Haematol. 2023;200(4):451-461. PubMed

Nachtkamp K, Stark R, Strupp C, et al. Causes of death in 2877 patients with myelodysplastic syndromes. Ann Hematol. 2016;95(6):937-944. PubMed

Kasprzak A, Andresen J, Nachtkamp K, et al. Infectious complications in patients with myelodysplastic syndromes: a report from the Düsseldorf MDS Registry. Cancers (Basel). 2024;16(4):808. PubMed PMC

Ontiveros-Austria J, Rodriguez-Rodriguez S, Demichelis R, González Lara MF, Apodaca Chavez EI. Risk factors associated to severe episodes of infection in myelodysplastic syndromes. Blood. 2023;142(Supplement 1):6493.

Toma A, Fenaux P, Dreyfus F, Cordonnier C. Infections in myelodysplastic syndromes. Haematologica. 2012;97(10):1459-1470. PubMed PMC

Kouroukli O, Symeonidis A, Foukas P, Maragkou MK, Kourea EP. Bone marrow immune microenvironment in myelodysplastic syndromes. Cancers (Basel). 2022;14(22):5656. PubMed PMC

Topping J, Taylor A, Nadat F, et al. Inflammatory profile of lower risk myelodysplastic syndromes. Br J Haematol. 2024;205(3):1044-1054. PubMed

Merkel D, Filanovsky K, Gafter-Gvili A, et al. Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: a retrospective multicenter study. Am J Hematol. 2013;88(2):130-134. PubMed

Sullivan LR, Sekeres MA, Shrestha NK, et al. Epidemiology and risk factors for infections in myelodysplastic syndromes. Transpl Infect Dis. 2013;15(6):652-657. PubMed

Leone G, Pagano L. Infections in myelodysplastic syndrome in relation to stage and therapy. Mediterr J Hematol Infect Dis. 2018;10(1):e2018039. PubMed PMC

Ofran Y, Filanovsky K, Gafter-Gvili A, et al. Higher infection rate after 7- compared with 5-day cycle of azacitidine in patients with higher-risk myelodysplastic syndrome. Clin Lymphoma Myeloma Leuk. 2015;15(6):e95-99. PubMed

de Swart L, Smith A, Johnston TW, et al. Validation of the Revised International Prognostic Scoring System (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) Registry. Br J Haematol. 2015;170(3):372-383. PubMed

Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100(7):2292-2302. PubMed

Pomeroy C, Oken MM, Rydell RE, Filice GA. Infection in the myelodysplastic syndromes. Am J Med. 1991;90(3):338-344. PubMed

Sebert M, Aguilar C, Chevret S, Ades L, Lortholary O, Fenaux P. Prognostic factors of infections and effect of primary anti-infectious prophylaxis in MDS patients treated with azacitidine (AZA): a prospective study. Blood. 2014;124(21):1917.

Cunningham I, MacCallum SJ, Nicholls MD, et al. The myelodysplastic syndromes: an analysis of prognostic factors in 226 cases from a single institution. Br J Haematol. 1995;90(3):602-606. PubMed

Sullivan LR, Sekeres MA, Shrestha NK, et al. Epidemiology and risk factors for infections in myelodysplastic syndromes. Transpl Infect Dis. 2013;15(6):652-657. PubMed

Ludwig N, Hilger A, Zarbock A, Rossaint J. Platelets at the crossroads of pro-inflammatory and resolution pathways during inflammation. Cells. 2022;11(12):1957. PubMed PMC

Page MJ, Pretorius E. A champion of host defense: a generic large-scale cause for platelet dysfunction and depletion in infection. Semin Thromb Hemost. 2020;46(3):302-319. PubMed PMC

Gascón P, Zoumbos NC, Young NS. Immunologic abnormalities in patients receiving multiple blood transfusions. Ann Intern Med. 1984;100(2):173-177. PubMed

Matsagos S, Verigou E, Kourakli A, et al. High frequency of post-transfusion microchimerism among multi-transfused beta-thalassemic patients. Front Med (Lausanne). 2022;9:845490. PubMed PMC

Smith BD, Mahmoud D, Dacosta-Byfield S, Rosen VM. Health care utilization and risk of infection and bleeding among patients with myelodysplastic syndromes with/without transfusions, and with/without active therapy. Leuk Lymphoma. 2014;55(5):1119-1125. PubMed PMC

Sakatoku K, Takeoka Y, Miura A, et al. Combination of frailty status and comorbidity score improves the stratification of survival in patients with myelodysplastic syndrome owing to good predictive capability for infection-related mortality. Clin Lymphoma Myeloma Leuk. 2019;19(12):799-805. PubMed

Saeed L, Patnaik MM, Begna KH, et al. Prognostic relevance of lymphocytopenia, monocytopenia and lymphocyte-to-monocyte ratio in primary myelodysplastic syndromes: a single center experience in 889 patients. Blood Cancer J. 2017;7(3):e550. PubMed PMC

Symeonidis A, Kourakli A, Katevas P, et al. Immune function parameters at diagnosis in patients with myelodysplastic syndromes: correlation with the FAB classification and prognosis. Eur J Haematol. 1991;47(4):277-281. PubMed

Cordonnier C, Maschmeyer G, Cesaro S, Ljungman P. Reporting infectious complications in haematology clinical trials should be improved. Clin Microbiol Infect. 2019;25(12):1451-1453. PubMed

Tau N, Shargian-Alon L, Reich S, et al. Reporting infections in clinical trials of patients with haematological malignancies. Clin Microbiol Infect. 2019;25(12):1494-1500. PubMed